Recent advances in the systemic management of colorectal cancer

Future Oncology

Volumn 2, Issue 5, 2006, Pages 643-650

  Mazhar, Danish ^a   Stebbing, Justin ^b   Heller, Wolfgang ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

5 fluorouracil; Bevacuzimab; Capecitabine targeted therapy; Cetuximab; Chemotherapy; Colorectal cancer; Irinotecan; Oxaliplatin

Indexed keywords

BEVACUZIMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PLACEBO; UNCLASSIFIED DRUG;

ALOPECIA; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL SURGERY; DEHYDRATION; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FATIGUE; HUMAN; INFECTION; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; TREATMENT OUTCOME; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; HUMANS; SURVIVAL RATE;

EID: 33750089261     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.2.5.643     Document Type: Review

References (43)

1. Toms JR (Ed.): Cancer Stats Monograph 2004. Cancer Research UK, London, UK (2004).
2. Gill S, Loprinzi CL, Sargent DJ et al.: Pooled analysis of fluorouracil-based adjuvant therapy for Stage II and III colon cancer: who benefits and by how? J. Clin. Oncol. 17, 3553-3559 (1999).
3. Moertel CG, Fleming TR, Macdonald JS et al.: Intergroup study of fluorouracil plus levamisole as adjuvant therapy for Stage II/Dukes' B2 colon cancer. J. Clin. Oncol. 13, 2936-2943 (1995).
4. Gray RG, Barnwell J, Hills R et al.: QUASAR: a randomised study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients. Proc. Am. Soc. Clin. Oncol. 22, 245 A3501 (2004).
5. Poplin E, Benedetti J, Estes N et al.: Phase III randomised trial of bolus 5HFU/leucovorin/levamisole versus 5-FU continuous infusion/ levamisole as adjuvant therapy for high risk colon cancer (SWOG 9415/ INT-0153). Proc. Am. Soc. Clin. Oncol. 19, A931 (2000).
6. Saini A, Norman AR, Cunningham D et al.: Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br. J. Cancer 88, 1859-1865 (2003).
7. Cassidy J, Scheithauer W, McKendrick J et al.: Capecitabine vs bolus 5-FU/leucovorin as adjuvant therapy for colon cancer (the X-ACT study): positive efficacy results of a Phase III trial. J. Clin. Oncol. 22(Suppl.) 3509 (2004).
8. Saltz LB, Niedzwiecki D, Hollis D et al.: Irinotecan plus fluorouracil/ leucovorin (IFL) versus fluorouracil alone (FL) in Stage III colon cancer (intergroup trial CALGB C89803). J. Clin. Oncol. 22(Suppl.) 3500 (2004).
9. Andre T, Boni C, Mounedji-Boudiaf L et al.: Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N. Eng. J. Med. 350, 2343-2351 (2004).
10. Barrat PL, Seymour MT, Stenning SP et al.: DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet 360, 1381-1391, (2002).
11. Al-Mulla F, Behbehani AI, Bitar MS, Varadharaj G, Going JJ: Genetic profiling of Stage I and II colorectal cancer may predict metastatic relapse. Mod. Pathol. 19, 648-658, (2006).
12. Cunningham D, Pyrhonen S, James RD et al.: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352, 1413-1418 (1998).
13. Rougier P, Van Custem E, Bejetta E et al.: Randomised trial of irinotecan versus flourouracil by continouus infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352, 1407-1412 (1998).
14. Saitz LB, Cox JV, Bianke C et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 343, 905-914 (2000).
15. Douillard JY, Cunningham D, Roth AD et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355, 1041-1047 (2000).
16. Rothenberg ML, Meropol NJ, Poplin EA et al.: Mortality associated with irinotecan plus fluorouracil/leucovorin: summary findings of an independent panel. J. Clin. Oncol. 19, 3801-3807 (2001).
17. Hwang JJ, Eisenberg SG, Marshall JL: Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day schedule. Oncology 17(Suppl. 8), 37-43 (2003).
18. Becouarn Y, Ychou M, Ducreux M et al.: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J. Clin. Oncol. 16, 2739-2744 (1998).
19. Diaz-Rubio E, Sastre J, Zaniboni A et al.: Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a Phase II multicentric study. Ann. Oncol. 9, 105-108 (1998).
20. de Gramont A, Figer A, Seymour M et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18, 2938-2947 (2000).
21. Giacchetti S, Perpoint B, Zidani R et al.: Phase III muticenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 18, 136-147 (2000).
22. Rothenberg ML, Oza AM, Bigelow RH et al: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a Phase III trial. J. Clin. Oncol. 21, 2059-2069 (2003).
23. de Gramont A, Bosset JF, Milan C et al.: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J. Clin. Oncol. 15, 808-815 (1997).
24. Adam R, Avisar E, Ariche A et al.: Five year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal liver metastases. Ann. Surg. Oncol. 8, 347-353 (2000).
25. Hoff PM, Ansari R, Batist G et al.: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized Phase III study. J. Clin. Oncol. 19, 2282-2292 (2001).
26. van Cutsern E, Twelves C, Cassidy J et al.: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large Phase III study. J. Clin. Oncol. 19, 4097-4106 (2001).
27. Twelve C: Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, Phase III trials. Eur. J. Cancer 38, 15-20 (2002).
28. Goldberg RM, Sargent DJ, Morton RF et al.: A randomized controlled trial of fluorouracil plus leocovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 22, 23-30 (2004).
29. Souglakos J, Androulakis N, Syrigos K et al.: FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and ironotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised Phase III trial from the Hellenic Oncology Research Group. Br. J. Cancer 94, 798-805 (2006).
30. Tournigand C, Andre T, Achille E et al.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 22, 229-237 (2004).
31. Grothey A, Jordan K, Kellner O et al.: Randomized Phase II trial of capecitabine plus irinotecan (CapIri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC). Prog. Proc. Am. Soc. Clin. Oncol. 22, 255 (2003).
32. Grothey A, Sargent D, Goldberg RM et al.: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J. Clin. Oncol. 22, 1209-1214 (2004).
33. Maindrault-Goebel F, Tournigand C, Andre T et al.: Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann. Oncol. 15, 1210-1214 (2004).
34. de Gramont A, Cervantes A, Andre T et al.: OPTIMOX study: FOLFOX7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. 22, 251 A3525 (2004).
35. Hurwitz H, Fehrenbacher L, Cartwright T et al.: Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a Phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc. Am. Soc. Clin. Oncol. 22, A3646 (2003).
36. Hurwitz H, Fehrenbacher L Novotny W et al.: Bevacizumab (Avastin) plus irinotecan, 5-fluorouracil, and leucovorin for metastatic colorectal cancer. N. Eng. J. Med. 350, 2335-2342 (2004).
37. Cunningham D, Humblet Y, Siena S et al.: Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc. Am. Soc. Clin. Oncol. 22(252) A1012 (2003).
38. Cunningham D, Humblet Y, Siena S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Eng. J. Med. 351, 337-345 (2004).
39. Kabbinavar F, Schulz J, McCleod M et al.: Bevacizumab (Avastin), a monoclonal antibody to vascular endothelial growth factor, prolongs progression-free survival in first-line colorectal cancer in subjects who are not suitable for first-line CPT-11. J. Clin. Oncol. 22(Suppl.) 3516 (2004).
40. Giantonio BJ, Catalano PJ, Meropol NJ et al.: High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results from Eastern Cooperative Group (ECOG) study E2300. Proceeding of: the 2005 Gastrointestinal Cancers Symposium. American Society of Clinical Oncology, Orlando, FL, USA, May 13-17 (2005).
41. Vincenzi B, Santini D, Rabitti C et al.: Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre Phase II trial. Br. J. Cancer 94, 792-797 (2006).
42. Steward W, Thomas A, Morgan B et al.: Expanded Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 22 (259) A2556 (2004).
43. Meyerhardt JA, Zhu AX, Enzinger PC et al.: Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J. Clin. Oncol. 24, 1892-1897 (2006).